Bryan Garnier - HYDROGENPRO ASA (HYPRO) HydrogenPro: Q3 results, partnership with J.H.K.

Report

Bryan Garnier

Mahaut Arnaud ...

Paul de Froment
Thomas Mordelle

HydrogenPro: Q3 results, partnership with J.H.K.

HydrogenPro has reported Q3 2024 results confirming a slowdown in 2024 vs 2023 due to lacking and postponed investment decisions for green hydrogen production. With revenue of NOK72m in Q3 2024 (YTD NOK126m vs FY24 cons. at NOK252m) the group has been accelerating its Salzgitter Flachstahl project

12/11/2024 1 EN

Underlying

HYDROGENPRO ASA

See profile

NO0010892359 Norway

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Mahaut Arnaud

Paul de Froment

Thomas Mordelle

Other Reports on these Companies

Bryan Garnier

HydrogenPro: up to NOK140m in equity financing from Andritz, MHI and Longi Hydrogen

HydrogenPro announced yesterday that it has secured (i) NOK70m in new equity from its existing strategic investors Andritz and Misubishi Heavy Industries (MHI) through a private placement, as well as (ii) an investment agreement for a conditional NOK70m equity investment and a cooperation agreement

December 24, 2024 December 24, 2024 1 EN

Bryan Garnier

HydrogenPro: slow pace in H1, waiting for new orders

HydrogenPro has reported Q2 2024 results confirming a slowdown compared to 2023. H1 2024 revenues came in at NOK54m vs NOK4m in Q1, significantly lower YoY (NOK221m in H1 2023) and 8% below cons. at NOK59m. Whereas a temporary reduction in activity was expected, transitioning from the completion of

August 20, 2024 August 20, 2024 1 EN

HydrogenPro: up to NOK140m in equity financing from Andritz, MHI and Longi Hydrogen

December 24, 2024 December 24, 2024 1 EN

Bruno Bulic ... (+3)

Bruno Bulic
Maria Vara
Oscar Haffen Lamm

Healthcare Outlook 2025

In our outlook for 2025, we:i) summarise the healthcare market performance in 2024,ii) take a look at ECM, M&A, and private financing trends and,iii) highlight our current conviction ideas for 2025: Abivax, Camurus, Medincell, Egetis, Valneva, Basilea, Onward, Bonesupport and Median.

December 20, 2024 December 20, 2024 1 EN

Antoine Lebourgeois

Antoine Lebourgeois

Vantiva: strategic refocus through divestiture of SCS

Vantiva has announced the sale of SCS to private equity funds for USD40m. Guidance has been updated to reflect SCS being reclassified under discontinued operations, with EBITDA for ongoing activities (i.e. CH division) now expected to exceed EUR100m, compared to the previous >EUR140m. This align

December 20, 2024 December 20, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

HydrogenPro: Q3 results, partnership with J.H.K.

HydrogenPro: up to NOK140m in equity financing from Andritz, MHI and Longi Hydrogen

HydrogenPro: slow pace in H1, waiting for new orders

HydrogenPro: up to NOK140m in equity financing from Andritz, MHI and Longi Hydrogen

Healthcare Outlook 2025

Vantiva: strategic refocus through divestiture of SCS

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe